Comprehensive Echocardiographic Assessment of Normal Transcatheter Valve Function

OBJECTIVES This study aims to establish parameters for identifying normal function for each of the 3 iterations of balloon-expandable valves and 2 iterations of self-expanding valves. BACKGROUND Expected transthoracic echocardiographic Doppler-derived hemodynamic data for transcatheter aortic valves inform pre-implant decision-making and post-implanted monitoring of longitudinal valve function. METHODS We collected the echocardiography core Lab measured mean gradients and effective orifice area (EOA) from discharge or 30-day echocardiograms from randomized trials; the PARTNER (Placement of Aortic Transcatheter Valves) trials for the balloon-expandable valves and the Medtronic CoreValve US Pivotal trial and Medtronic CoreValve Evolut R United States IDE Clinical Study for the self-expanding valves. RESULTS For all SAPIEN (Edwards Lifesciences, Irvine, California) valve sizes, mean EOA is 1.70 +/- 0.49 cm(2) with a mean gradient of 9.36 +/- 4.13 mm Hg. For all SAPIEN XT valve sizes, mean EOA is L67 +/- 0.46 cm(2) with a mean gradient of 9.52 +/- 3.64 mm Hg. For all SAPIEN 3 valve sizes, the mean EOA is 1.66 +/- 0.38 cm(2) with a mean gradient of 11.18 +/- 4.35 mm Hg. For all CoreValve valve sizes, the mean EOA is 1.88 +/- 0.56 cm(2) with a mean gradient of 8.85 +/- 4.14 mm Hg. For all Evolut R valve sizes, the mean EOA is 2.01 +/- 0.65 cm(2) with a mean gradient of 7.52 +/- 3.19 mm Hg. The SAPIEN 3 post-implant EOA was progressively larger for each quintile of baseline annular area by computed tomography (p < 0.001). Similarly, for the Evolut R valve, post-implantation EOA was significantly larger for each quintile of baseline annular perimeter (p < 0.001). CONCLUSIONS Tables of expected mean transcatheter aortic valve hemodynamics by valve type and size are essential in evaluating the function of these transcatheter prosthetic valves. Tables of expected EOA by the native annular anatomy may be useful for pre-implantation decision making. Criteria for defining structural valve dysfunction are proposed. (C) 2019 by the American College of Cardiology Foundation.